// App-Quantinova.ai

PB0911 : Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study

Researchers

Presenter

  • A. Cohen

Principal Investigators

  • C. Wallenhorst

  • C. Becattini

  • B. Schaefer

  • G. Brobert

  • C. Coleman

  • A. Ekbom

  • C. Ay

  • A. Lee

  • A. Khorana

  • M. Carrier

  • M. Rivera

Medical Centers

  • Department of Haematology Medicine, Guy's and St Thomas' NHS Foundation Trust, London, England, United Kingdom

  • Institute for Epidemiology, Statistics and Informatics, Frankfurt, Germany

  • University of Perugia, Italy, Perugia, Umbria, Italy

  • Bayer AG Medical Affairs & Pharmacovigilance, Pharmaceuticals, Berlin, Berlin, Germany

  • Integrated Evidence Generation & Business Innovation, Bayer AB, stockholm, Stockholms Lan, Sweden

  • School of Pharmacy, University of Connecticut, Hartford, Connecticut, United States

  • Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

  • Dept. of Medicine I, Div. of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

  • Division of Hematology, Department of Medicine, St. Pauls Hospital and University of British Columbia, Vancouver, BC, Canada

  • Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH

  • University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

  • Integrated Evidence Generation & Business Innovation, Bayer AG, Berlin, Berlin, Germany

Locations

  • United Kingdom

  • Germany

  • Italy

  • Sweden

  • United States

  • Austria

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Nephrology

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • End stage renal disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Arrhythmia

  • Pulmonary embolism

  • Thrombocytopenia

  • Renal insufficiency

  • Solid malignancies

Biomarkers

  • Catalase

Drug/Treatment

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved